- Home
- ARQT vs COMM Comparison
ARQT vs COMM Comparison
Compare ARQT & COMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- COMM
- Stock Information
- Founded
- ARQT 2016
- COMM 1976
- Country
- ARQT United States
- COMM United States
- Employees
- ARQT N/A
- COMM N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- COMM Radio And Television Broadcasting And Communications Equipment
- Sector
- ARQT Health Care
- COMM Technology
- Exchange
- ARQT Nasdaq
- COMM Nasdaq
- Market Cap
- ARQT 1.1B
- COMM 1.1B
- IPO Year
- ARQT 2020
- COMM 2013
- Fundamental
- Price
- ARQT $13.92
- COMM $5.39
- Analyst Decision
- ARQT Strong Buy
- COMM Hold
- Analyst Count
- ARQT 5
- COMM 5
- Target Price
- ARQT $17.00
- COMM $3.00
- AVG Volume (30 Days)
- ARQT 2.2M
- COMM 4.4M
- Earning Date
- ARQT 02-25-2025
- COMM 02-27-2025
- Dividend Yield
- ARQT N/A
- COMM N/A
- EPS Growth
- ARQT N/A
- COMM N/A
- EPS
- ARQT N/A
- COMM N/A
- Revenue
- ARQT $138,708,000.00
- COMM $5,183,800,000.00
- Revenue This Year
- ARQT $209.03
- COMM N/A
- Revenue Next Year
- ARQT $49.00
- COMM N/A
- P/E Ratio
- ARQT N/A
- COMM N/A
- Revenue Growth
- ARQT 182.84
- COMM 21.78
- 52 Week Low
- ARQT $3.11
- COMM $0.86
- 52 Week High
- ARQT $16.20
- COMM $7.19
- Technical
- Relative Strength Index (RSI)
- ARQT 51.79
- COMM 51.46
- Support Level
- ARQT $13.10
- COMM $4.75
- Resistance Level
- ARQT $16.20
- COMM $5.61
- Average True Range (ATR)
- ARQT 0.95
- COMM 0.36
- MACD
- ARQT -0.26
- COMM -0.03
- Stochastic Oscillator
- ARQT 26.45
- COMM 58.72
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About COMM CommScope Holding Company Inc.
CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center and entertainment networks. The company provides solutions for wired and wireless networks to enable service providers, including cable, telephone, data center and digital broadcast satellite operators and media programmers, to deliver media, voice, Internet Protocol (IP) data services and Wi-Fi to their subscribers and allow enterprises to experience constant wireless and wired connectivity across complex and varied networking environments. They have operating segments, which excludes our Home segment: Connectivity and Cable Solutions (CCS), Outdoor Wireless Networks (OWN), Networking, Intelligent Cellular and Security Solutions (NICS) and Access Network Solutions (ANS).